Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

Vancomycin remains the mainstay treatment for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs) despite increased treatment failures. Daptomycin has been shown to improve clinical outcomes in patients with BSIs caused by MRSA isolates with vancomycin MICs of >1 mg/l...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antimicrobial agents and chemotherapy 2016-10, Vol.60 (10), p.5841-5848
Hauptverfasser:	Claeys, Kimberly C, Zasowski, Evan J, Casapao, Anthony M, Lagnf, Abdalhamid M, Nagel, Jerod L, Nguyen, Cynthia T, Hallesy, Jessica A, Compton, Mathew T, Kaye, Keith S, Levine, Donald P, Davis, Susan L, Rybak, Michael J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Bacteremia Bacteremia - drug therapy Bacteremia - microbiology Bacteremia - mortality Clinical Therapeutics Cohort Studies Daptomycin Daptomycin - adverse effects Daptomycin - therapeutic use Humans Intensive Care Units Length of Stay Methicillin-Resistant Staphylococcus aureus Methicillin-Resistant Staphylococcus aureus - drug effects Methicillin-Resistant Staphylococcus aureus - pathogenicity Microbial Sensitivity Tests - methods Middle Aged Retrospective Studies Staphylococcal Infections Staphylococcal Infections - drug therapy Staphylococcal Infections - microbiology Staphylococcal Infections - mortality Staphylococcus aureus Treatment Outcome Vancomycin Vancomycin - adverse effects Vancomycin - pharmacology Vancomycin - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!